Detalles de la búsqueda
1.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 25(5): 572-587, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38561010
2.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 73(4): 70, 2024 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38430375
3.
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Drug Resist Updat
; 60: 100806, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35121337
4.
International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.
Lancet Oncol
; 23(12): e544-e551, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455583
5.
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
Oncologist
; 27(10): e783-e795, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36124924
6.
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Breast Cancer Res
; 22(1): 36, 2020 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32295625
7.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Lancet
; 393(10167): 156-167, 2019 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30509740
8.
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
Future Oncol
; 16(18): 1235-1243, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32490686
9.
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncol
; 20(3): 383-393, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745090
10.
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
Curr Opin Oncol
; 31(3): 122-130, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30986809
11.
Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.
Urol Int
; 100(3): 357-360, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-26845702
12.
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Cancer
; 122(24): 3803-3811, 2016 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27525588
13.
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.
Oncologist
; 21(5): 535-6, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27091421
14.
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Oncologist
; 21(12): 1416-e17, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27903924
15.
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
BJU Int
; 118(3): 408-15, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26779597
16.
Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.
Curr Treat Options Oncol
; 17(7): 37, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27262711
17.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Lancet Oncol
; 16(5): 583-94, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25892145
18.
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
BJU Int
; 115(5): 744-52, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24947139
19.
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
Urol Int
; 94(4): 485-7, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25531760
20.
Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck.
Radiol Oncol
; 49(1): 17-25, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25810697